Worku Bekele
Overview
Explore the profile of Worku Bekele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tesfaye M, Assefa A, Hailgiorgis H, Gidey B, Mohammed H, Tollera G, et al.
Malar J
. 2024 Jun;
23(1):184.
PMID: 38867217
Background: Malaria remains a major global health problem although there was a remarkable achievement between 2000 and 2015. Malaria drug resistance, along with several other factors, presents a significant challenge...
2.
Mare A, Mohammed H, Sime H, Hailgiorgis H, Gubae K, Gidey B, et al.
Malar J
. 2024 Jun;
23(1):183.
PMID: 38858696
Background: Plasmodium vivax malaria is a leading cause of morbidity in Ethiopia. The first-line treatment for P. vivax is chloroquine (CQ) and primaquine (PQ), but there have been local reports...
3.
Alebachew M, Gelaye W, Abate M, Sime H, Hailgiorgis H, Gidey B, et al.
Malar J
. 2023 Jun;
22(1):186.
PMID: 37330475
Background: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports...
4.
Assefa A, Mohammed H, Anand A, Abera A, Sime H, Minta A, et al.
Malar J
. 2023 Apr;
22(1):121.
PMID: 37041533
No abstract available.
5.
Belay H, Alemu M, Hailu T, Mohammed H, Sime H, Hailegeorgies H, et al.
PLoS One
. 2023 Jan;
18(1):e0277362.
PMID: 36634046
Background: The development of drug resistance to chloroquine is posing a challenge in the prevention and control efforts of malaria globally. Chloroquine is the first-line treatment for uncomplicated P.vivax in...
6.
Gubae K, Mohammed H, Sime H, Hailgiorgis H, Mare A, Gidey B, et al.
Malar J
. 2023 Jan;
22(1):9.
PMID: 36611179
Background: In 2004, Ethiopia adopted artemether-lumefantrine (AL, Coartem) as first-line treatment for the management of uncomplicated Plasmodium falciparum malaria. Continuous monitoring of AL therapeutic efficacy is crucial in Ethiopia, as...
7.
Mohammed H, Sime H, Hailgiorgis H, Chernet M, Alebachew M, Solomon H, et al.
Malar J
. 2022 Dec;
21(1):401.
PMID: 36587210
Background: Declining efficacy of chloroquine for the treatment Plasmodium vivax malaria has been reported in different endemic settings in Ethiopia. This highlights the need to assess alternative options for P....
8.
Assefa A, Mohammed H, Anand A, Abera A, Sime H, Minta A, et al.
Malar J
. 2022 Dec;
21(1):359.
PMID: 36451216
Background: Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the national treatment guidelines employ a species-specific...
9.
Mohammed H, Sime H, Hailgiorgis H, Gubae K, Haile M, Solomon H, et al.
Malar J
. 2022 Nov;
21(1):351.
PMID: 36437454
Background: Declining efficacy of chloroquine against Plasmodium vivax malaria has been documented in Ethiopia. Thus, there is a need to assess the efficacy of alternative schizontocidal anti-malarials such as dihydroartemisinin-piperaquine...
10.
Nega D, Abera A, Gidey B, Mekasha S, Abebe A, Dillu D, et al.
BMC Public Health
. 2021 Nov;
21(1):1996.
PMID: 34732150
Background: Encouraged by the previous success in malaria control and prevention strategies, the Ethiopian ministry of health launched malaria elimination with a stepwise approach by primarily targeting the low-transmission Districts...